102 related articles for article (PubMed ID: 18724493)
41. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V
Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
[TBL] [Abstract][Full Text] [Related]
42. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
43. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
Katzenstein DA
AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
[No Abstract] [Full Text] [Related]
44. Labeling changes for Reyataz.
AIDS Patient Care STDS; 2008 Sep; 22(9):761. PubMed ID: 18802976
[No Abstract] [Full Text] [Related]
45. Clinical pharmacology of HIV protease inhibitors in pregnancy.
van der Lugt J; Colbers A; Burger D
Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
[TBL] [Abstract][Full Text] [Related]
46. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
[TBL] [Abstract][Full Text] [Related]
47. Two newcomers may challenge ritonavir's position as the only booster for HIV therapy.
Proj Inf Perspect; 2009 Mar; (48):10-1. PubMed ID: 19492462
[No Abstract] [Full Text] [Related]
48. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
Wilkins E
J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
[No Abstract] [Full Text] [Related]
49. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
[No Abstract] [Full Text] [Related]
50. Wyeth preemption case ruling sparks labeling confusion.
Allison M
Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
[No Abstract] [Full Text] [Related]
51. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.
Dickinson L; Khoo S; Back D
Curr Opin HIV AIDS; 2008 May; 3(3):296-305. PubMed ID: 19372982
[TBL] [Abstract][Full Text] [Related]
52. 13th annual HIV drug guide.
Djuricich P; Vázquez E
Posit Aware; 2009; 20(2):28-55. PubMed ID: 19280745
[No Abstract] [Full Text] [Related]
53. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
54. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
Lapins M; Wikberg JE
J Chem Inf Model; 2009 May; 49(5):1202-10. PubMed ID: 19391634
[TBL] [Abstract][Full Text] [Related]
55. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
56. Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.
Trudel N; Garg R; Messier N; Sundar S; Ouellette M; Tremblay MJ
J Infect Dis; 2008 Nov; 198(9):1292-9. PubMed ID: 18816190
[TBL] [Abstract][Full Text] [Related]
57. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
58. Five years later: re-examining the financial burden of boosting with Norvir.
Marquez C; Guglielmo BJ; Klausner JD
AIDS; 2008 Nov; 22(17):2402-4. PubMed ID: 18981784
[No Abstract] [Full Text] [Related]
59. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
60. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.
Monini P; Sgadari C; Grosso MG; Bellino S; Di Biagio A; Toschi E; Bacigalupo I; Sabbatucci M; Cencioni G; Salvi E; Leone P; Ensoli B
AIDS; 2009 Feb; 23(4):534-8. PubMed ID: 19169139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
